A new study conducted by Clinical Research Australia has reinforced the stress-reducing potential of Natural Remedies’ Ashwa.30, a next-generation ashwagandha extract.
Natural Remedies will present the results at SupplySide Global in Las Vegas and CPHI Global in Frankfurt, Germany, later this month.
The randomised, double-blind, placebo-controlled trial titled “Efficacy and tolerability of Ashwa.30 in reducing stress: Findings from a recent third clinical study,” enrolled 60 healthy adults experiencing elevated stress.
Participants received either 30 mg of Ashwa.30 daily or a matched placebo.
Results showed a statistically significant reduction in perceived stress among those taking Ashwa.30.
Participants in the Ashwa.30 group recorded a mean decrease of 8.54 stress subscore points on the Depression Anxiety Stress Scale and a 43.9% improvement from baseline.
Cortisol response to induced stress also differed sharply between groups, rising only 18.93% in the Ashwa.30 group compared to an 86.17% increase in the placebo group.
No significant side effects were reported.
“These findings strengthen the scientific foundation behind Ashwa.30’s adaptogenic benefits,” said Suresh Lakshmikanthan, Chief Business Officer at Natural Remedies.
“At just 30 mg, Ashwa.30 demonstrates a meaningful impact on both psychological and physiological stress markers, which is noteworthy given that most ashwagandha studies use much higher doses.”
Ashwa.30 was developed using Natural Remedies’ proprietary Bioactive Optimisation Technology (BOT), which integrates traditional herbal knowledge with modern biology and data analytics to isolate the most effective bioactive compounds.
Previous clinical studies found that Ashwa.30 reduced salivary cortisol levels by nearly 40% in just seven days and improved endurance eightfold, as measured by VO₂ max testing.
Pre-clinical findings suggest enhanced aerobic energy production and reduced fatigue due to lower lactic acid buildup.
“Our goal is to advance evidence-based herbal ingredients that deliver efficacy at low doses while maintaining sustainability and ethical sourcing standards,” said Lakshmikanthan.
“We work directly with farmers through guaranteed buy-back programmes to grow ashwagandha using sustainable practices.”
The Natural Remedies team will highlight the new data on Ashwa.30 at a breakfast briefing during SupplySide Global, at 9 am on October 30 in the Mandalay Bay Convention Centre’s South Pacific Ballroom A.
This will be led by Deepak Mundkinajeddu, Head of Research, Development and Quality.
Natural Remedies will also exhibit at SupplySide Global on October 27-30 (booth 6047) and CPHI Global on October 28-30 (stand 12.1D109).